Vijay Pande on Scaling a16z Bio & Health: High-Conviction VC Bets in 2026

In an exclusive discussion following his management of $4 billion at Andreessen Horowitz, Vijay Pande explained why a16z Bio & Health is prioritizing high-conviction, concentrated startup investments over high-volume indexing.

Speaking on the evolution of venture capital in synthetic biology and healthcare, Andreessen Horowitz General Partner Vijay Pande outlined a decisive shift in investment philosophy. Rather than deploying capital across dozens of early-stage startups per year, a16z Bio & Health is focusing on concentrated, high-conviction bets.

Pande emphasized that the convergence of computational biology, generative AI foundation models, and robotic wet-lab automation has fundamentally altered startup capital requirements. Successful biotech companies now require substantial upfront capital to build proprietary wet-lab data feedback loops rather than incremental seed funding.

The firm's refined strategy aims to support breakout platforms capable of end-to-end drug candidate design, clinical trial orchestration, and automated genomic analysis, positioning AI-driven biotech as a prime pillar of venture returns.